Blue Flower

Usage of Cookies
We use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about our use of cookies can be found in our privacy policy. If you continue to use this website we will assume that you agree with the usage of cookies. You can prevent cookies from being installed or delete them from your computer. How this works, is explained in our privacy policy. Imprint

Dear Madam, Dear Sir

On behalf of the entire NOXXON team, I am pleased to welcome you to this section of our website. NOXXON is a European biopharmaceutical company developing anticancer treatments targeting the tumor microenvironment and is listed on Euronext Growth in Paris, formerly Alternext.

Our goal is to significantly improve cancer therapies, including immuno-oncology approaches, such as checkpoint inhibitors, and standard therapies such as chemo- and radio-therapy.

During 2019 we have continued to follow the patients in combination trial of NOX-A12 + immunotherapy in colorectal and pancreatic cancers in which was conducted in collaboration with Merck & Co/MSD to assess the safety and activity of NOX-A12 in patients with advanced cancer.
We initiated recruitment for an additional combination trial of NOX-A12 with radiotherapy in brain cancer patients in September 2019.

Best regards

Aram Mangasarian, PhD
Chief Executive Officer

• Download the initiation report on NOXXON by Aurgalys
➥ See latest update note from Aurgalys here
• Download the re-initiation report (Dec 2018) on NOXXON by Invest Securities
 ➥ See latest update note from Invest Security here


L’entretien avec Aram Mangasarian, PDG de Noxxon, dans Le journal des biotechs de Boursorama pour brosser les perspectives de la société et de ses deux produits NOX-A12 et NOX-E36.
Le PDG de NOXXON Pharma annonce le transfert de l’action vers le compartiment EURONEXT GROWTH pour être cotée en continu.
NOXXON CEO Aram Mangasarian talks to Scrip about development plans for the company's lead compound NOX-A12, which is being tested as a combination therapy for a number of cancer indications on BIO-Europe Spring 2017